What is Vertex Pharmaceuticals Inc's earnings per share (EPS)?

Vertex Pharmaceuticals Inc (VRTX) reported diluted earnings per share of $15.32 for fiscal year 2025. This represents a 836.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Vertex Pharmaceuticals Inc Financials

VRTX

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Vertex Pharmaceuticals Inc (VRTX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 18 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 75/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Vertex Pharmaceuticals Inc has an operating margin of 34.8%, meaning the company retains $35 of operating profit per $100 of revenue. This strong profitability earns a score of 99/100, reflecting efficient cost management and pricing power. This is up from -2.1% the prior year.

Growth

Vertex Pharmaceuticals Inc's revenue grew 8.9% year-over-year to $12.0B, a solid pace of expansion. This earns a growth score of 48/100.

Leverage

Vertex Pharmaceuticals Inc carries a low D/E ratio of 0.37, meaning only $0.37 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 94/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Vertex Pharmaceuticals Inc's current ratio of 2.90 indicates adequate short-term liquidity, earning a score of 55/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

Vertex Pharmaceuticals Inc converts 26.6% of revenue into free cash flow ($3.2B). This strong cash generation earns a score of 92/100.

Returns

Vertex Pharmaceuticals Inc's ROE of 21.2% shows moderate profitability relative to equity, earning a score of 58/100. This is up from -3.3% the prior year.

Altman Z-Score Safe

11.67

Vertex Pharmaceuticals Inc scores 11.67, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($111.4B) relative to total liabilities ($7.0B). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Piotroski F-Score Neutral

6/9

Vertex Pharmaceuticals Inc passes 6 of 9 financial strength tests. 3 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Mixed

0.92x

For every $1 of reported earnings, Vertex Pharmaceuticals Inc generates $0.92 in operating cash flow ($3.6B OCF vs $4.0B net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.

Interest Coverage Safe

313.8x

Vertex Pharmaceuticals Inc earns $313.8 in operating income for every $1 of interest expense ($4.2B vs $13.3M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$12.0B

YoY+8.9%

5Y CAGR+14.1%

10Y CAGR+27.8%

Vertex Pharmaceuticals Inc generated $12.0B in revenue in fiscal year 2025. This represents an increase of 8.9% from the prior year.

EBITDA

$4.4B

YoY+17154.9%

5Y CAGR+8.1%

Vertex Pharmaceuticals Inc's EBITDA was $4.4B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 17154.9% from the prior year.

Net Income

$4.0B

YoY+838.1%

5Y CAGR+7.8%

Vertex Pharmaceuticals Inc reported $4.0B in net income in fiscal year 2025. This represents an increase of 838.1% from the prior year.

EPS (Diluted)

$15.32

YoY+836.5%

5Y CAGR+8.3%

Vertex Pharmaceuticals Inc earned $15.32 per diluted share (EPS) in fiscal year 2025. This represents an increase of 836.5% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$3.2B

YoY+504.1%

5Y CAGR+1.3%

Vertex Pharmaceuticals Inc generated $3.2B in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 504.1% from the prior year.

Cash & Debt

$5.1B

YoY+11.3%

5Y CAGR-3.2%

10Y CAGR+21.7%

Vertex Pharmaceuticals Inc held $5.1B in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

254M

YoY-1.1%

5Y CAGR-0.5%

10Y CAGR+0.3%

Vertex Pharmaceuticals Inc had 254M shares outstanding in fiscal year 2025. This represents a decrease of 1.1% from the prior year.

Margins & Returns

Gross Margin

86.2%

YoY+0.1pp

5Y CAGR-1.9pp

10Y CAGR-2.4pp

Vertex Pharmaceuticals Inc's gross margin was 86.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 0.1 percentage points from the prior year.

Operating Margin

34.8%

YoY+36.9pp

5Y CAGR-11.3pp

10Y CAGR+80.0pp

Vertex Pharmaceuticals Inc's operating margin was 34.8% in fiscal year 2025, reflecting core business profitability. This is up 36.9 percentage points from the prior year.

Net Margin

32.9%

YoY+37.8pp

5Y CAGR-10.8pp

10Y CAGR+86.8pp

Vertex Pharmaceuticals Inc's net profit margin was 32.9% in fiscal year 2025, showing the share of revenue converted to profit. This is up 37.8 percentage points from the prior year.

Return on Equity

21.2%

YoY+24.4pp

5Y CAGR-10.0pp

10Y CAGR+80.4pp

Vertex Pharmaceuticals Inc's ROE was 21.2% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 24.4 percentage points from the prior year.

Capital Allocation

R&D Spending

$3.9B

YoY+7.7%

5Y CAGR+16.4%

10Y CAGR+14.7%

Vertex Pharmaceuticals Inc invested $3.9B in research and development in fiscal year 2025. This represents an increase of 7.7% from the prior year.

Share Buybacks

$2.0B

YoY+71.4%

5Y CAGR+30.2%

Vertex Pharmaceuticals Inc spent $2.0B on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents an increase of 71.4% from the prior year.

Capital Expenditures

$437.6M

YoY+47.0%

5Y CAGR+11.0%

10Y CAGR+25.5%

Vertex Pharmaceuticals Inc invested $437.6M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 47.0% from the prior year.

VRTX Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$12.0B+8.9%	$11.0B+11.7%	$9.9B+10.5%	$8.9B+17.9%	$7.6B+22.1%	$6.2B
Cost of Revenue	$1.7B+7.9%	$1.5B+21.3%	$1.3B+16.8%	$1.1B+19.5%	$904.2M+22.8%	$736.3M
Gross Profit	$10.3B+9.1%	$9.5B+10.3%	$8.6B+9.6%	$7.9B+17.7%	$6.7B+22.0%	$5.5B
R&D Expenses	$3.9B+7.7%	$3.6B+14.8%	$3.2B+24.5%	$2.5B-16.7%	$3.1B+66.8%	$1.8B
SG&A Expenses	$1.8B+19.7%	$1.5B+28.8%	$1.1B+20.3%	$944.7M+12.5%	$840.1M+9.0%	$770.5M
Operating Income	$4.2B+1891.9%	-$232.9M-106.1%	$3.8B-11.0%	$4.3B+54.8%	$2.8B-2.6%	$2.9B
Interest Expense	$13.3M-56.5%	$30.6M-30.6%	$44.1M-19.5%	$54.8M+189.1%	-$61.5M-205.8%	$58.2M
Income Tax	$690.0M-12.0%	$784.1M+3.1%	$760.2M-16.5%	$910.4M+134.5%	$388.3M-4.2%	$405.2M
Net Income	$4.0B+838.1%	-$535.6M-114.8%	$3.6B+9.0%	$3.3B+41.8%	$2.3B-13.6%	$2.7B
EPS (Diluted)	$15.32+836.5%	$-2.08-115.0%	$13.89+8.3%	$12.82+42.3%	$9.01-12.4%	$10.29

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$3.2B+3.7%	$3.1B+3.8%	$3.0B+7.0%	$2.8B-4.9%	$2.9B+5.1%	$2.8B+4.8%	$2.6B-1.7%	$2.7B
Cost of Revenue	$466.0M+12.3%	$414.8M+1.8%	$407.5M+12.3%	$363.0M-14.3%	$423.4M+7.8%	$392.6M+5.6%	$371.9M+8.6%	$342.6M
Gross Profit	$2.7B+2.3%	$2.7B+4.1%	$2.6B+6.2%	$2.4B-3.3%	$2.5B+4.6%	$2.4B+4.6%	$2.3B-3.2%	$2.3B
R&D Expenses	$973.7M-0.4%	$977.7M-0.1%	$978.4M-0.1%	$979.7M-1.9%	$998.7M+14.0%	$875.9M-9.4%	$966.6M+22.5%	$789.1M
SG&A Expenses	$487.0M+9.4%	$445.1M+4.8%	$424.6M+7.1%	$396.4M+5.0%	$377.6M+1.6%	$371.8M-0.1%	$372.2M+8.6%	$342.7M
Operating Income	$1.2B+1.7%	$1.2B+3.0%	$1.2B+82.7%	$630.1M-38.6%	$1.0B-8.1%	$1.1B+131.8%	-$3.5B-408.4%	$1.1B
Interest Expense	$3.3M0.0%	$3.3M-10.8%	$3.7M+23.3%	$3.0M+7.1%	$2.8M-62.7%	$7.5M-24.2%	$9.9M-4.8%	$10.4M
Income Tax	$139.9M-35.2%	$215.9M-13.7%	$250.1M+197.4%	$84.1M-62.4%	$223.5M+25.1%	$178.7M-11.7%	$202.4M+12.8%	$179.5M
Net Income	$1.2B+10.0%	$1.1B+4.8%	$1.0B+59.8%	$646.3M-29.2%	$913.0M-12.7%	$1.0B+129.1%	-$3.6B-426.8%	$1.1B
EPS (Diluted)	N/A	$4.20+5.3%	$3.99+60.2%	$2.49	N/A	$4.01+128.8%	$-13.92-430.6%	$4.21

VRTX Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$25.6B+13.8%	$22.5B-0.9%	$22.7B+25.2%	$18.2B+35.1%	$13.4B+14.3%	$11.8B
Current Assets	$11.2B+16.7%	$9.6B-32.2%	$14.1B+6.9%	$13.2B+38.4%	$9.6B+17.5%	$8.1B
Cash & Equivalents	$5.1B+11.3%	$4.6B-55.9%	$10.4B-1.3%	$10.5B+54.6%	$6.8B+13.5%	$6.0B
Inventory	$1.7B+39.9%	$1.2B+63.2%	$738.8M+60.4%	$460.6M+30.4%	$353.1M+25.7%	$280.8M
Accounts Receivable	$2.1B+27.6%	$1.6B+2.9%	$1.6B+8.4%	$1.4B+26.9%	$1.1B+28.4%	$885.4M
Goodwill	$1.1B0.0%	$1.1B0.0%	$1.1B0.0%	$1.1B+8.6%	$1.0B0.0%	$1.0B
Total Liabilities	$7.0B+13.9%	$6.1B+18.9%	$5.1B+21.5%	$4.2B+27.2%	$3.3B+8.7%	$3.1B
Current Liabilities	$3.9B+8.3%	$3.6B+0.5%	$3.5B+29.4%	$2.7B+28.0%	$2.1B+14.1%	$1.9B
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$18.7B+13.7%	$16.4B-6.7%	$17.6B+26.4%	$13.9B+37.7%	$10.1B+16.3%	$8.7B
Retained Earnings	$13.6B+41.2%	$9.6B-5.3%	$10.1B+55.5%	$6.5B+103.8%	$3.2B+272.7%	$858.7M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$25.6B+3.1%	$24.9B+3.4%	$24.0B+5.1%	$22.9B+1.5%	$22.5B+1.3%	$22.2B+10.5%	$20.1B-15.8%	$23.9B
Current Assets	$11.2B+6.0%	$10.6B+1.4%	$10.4B+4.2%	$10.0B+4.3%	$9.6B-2.1%	$9.8B+9.6%	$8.9B-32.7%	$13.3B
Cash & Equivalents	$5.1B+2.9%	$4.9B-0.7%	$5.0B+6.4%	$4.7B+2.3%	$4.6B-12.8%	$5.2B+14.4%	$4.6B-50.0%	$9.2B
Inventory	$1.7B+3.7%	$1.6B+8.5%	$1.5B+10.3%	$1.4B+12.8%	$1.2B+11.6%	$1.1B+18.1%	$914.6M+12.5%	$813.1M
Accounts Receivable	$2.1B+5.5%	$1.9B+2.8%	$1.9B+4.9%	$1.8B+12.2%	$1.6B-8.1%	$1.8B+5.7%	$1.7B-7.6%	$1.8B
Goodwill	$1.1B0.0%	$1.1B0.0%	$1.1B0.0%	$1.1B0.0%	$1.1B0.0%	$1.1B0.0%	$1.1B0.0%	$1.1B
Total Liabilities	$7.0B-7.5%	$7.5B+9.9%	$6.9B+7.5%	$6.4B+4.3%	$6.1B-7.3%	$6.6B+23.4%	$5.4B-0.2%	$5.4B
Current Liabilities	$3.9B-13.7%	$4.5B+8.1%	$4.1B+9.4%	$3.8B+6.1%	$3.6B-10.3%	$4.0B+12.0%	$3.5B-6.6%	$3.8B
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$18.7B+7.8%	$17.3B+0.8%	$17.2B+4.1%	$16.5B+0.5%	$16.4B+5.0%	$15.6B+5.8%	$14.8B-20.3%	$18.5B
Retained Earnings	$13.6B+9.6%	$12.4B+9.6%	$11.3B+10.1%	$10.3B+6.7%	$9.6B+10.5%	$8.7B+13.7%	$7.6B-32.0%	$11.2B

VRTX Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$3.6B+837.2%	-$492.6M-113.9%	$3.5B-14.3%	$4.1B+56.2%	$2.6B-18.7%	$3.3B
Capital Expenditures	$437.6M+47.0%	$297.7M+48.6%	$200.4M-2.1%	$204.7M-12.9%	$235.0M-9.5%	$259.8M
Free Cash Flow	$3.2B+504.1%	-$790.3M-123.7%	$3.3B-15.0%	$3.9B+63.0%	$2.4B-19.5%	$3.0B
Investing Cash Flow	-$945.4M+74.9%	-$3.8B-20.0%	-$3.1B-878.4%	-$321.1M+5.8%	-$340.9M-443.0%	$99.4M
Financing Cash Flow	-$2.3B-51.3%	-$1.5B-165.9%	-$562.2M-730.4%	-$67.7M+95.4%	-$1.5B-192.5%	-$505.3M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$2.0B+71.4%	$1.2B+175.3%	$427.6M	$0-100.0%	$1.4B+164.4%	$539.1M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	$498.0M-59.9%	$1.2B+15.7%	$1.1B+31.0%	$818.9M+40.1%	$584.6M-57.3%	$1.4B+136.5%	-$3.8B-387.3%	$1.3B
Capital Expenditures	$149.4M+46.8%	$101.8M-30.1%	$145.7M+258.0%	$40.7M-56.0%	$92.6M+36.8%	$67.7M-1.9%	$69.0M+0.9%	$68.4M
Free Cash Flow	$348.6M-69.4%	$1.1B+22.9%	$927.4M+19.2%	$778.2M+58.2%	$492.0M-62.2%	$1.3B+134.1%	-$3.8B-408.7%	$1.2B
Investing Cash Flow	-$288.1M-146.2%	-$117.0M+75.9%	-$484.5M-768.3%	-$55.8M+93.2%	-$821.9M-136.2%	-$348.0M+25.0%	-$463.7M+78.3%	-$2.1B
Financing Cash Flow	-$77.2M+93.3%	-$1.2B-230.6%	-$349.2M+48.7%	-$680.4M-73.9%	-$391.3M-1.0%	-$387.5M-8.1%	-$358.6M-0.3%	-$357.5M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$128.4M-88.0%	$1.1B+173.4%	$391.8M-8.0%	$426.1M+2.0%	$417.9M+35.8%	$307.7M-3.9%	$320.3M+144.1%	$131.2M

VRTX Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	86.2%+0.1pp	86.1%-1.1pp	87.2%-0.7pp	87.9%-0.2pp	88.1%-0.1pp	88.1%
Operating Margin	34.8%+36.9pp	-2.1%-40.9pp	38.8%-9.4pp	48.2%+11.5pp	36.7%-9.3pp	46.0%
Net Margin	32.9%+37.8pp	-4.9%-41.5pp	36.7%-0.5pp	37.2%+6.3pp	30.9%-12.8pp	43.7%
Return on Equity	21.2%+24.4pp	-3.3%-23.8pp	20.6%-3.3pp	23.9%+0.7pp	23.2%-8.0pp	31.2%
Return on Assets	15.4%+17.8pp	-2.4%-18.3pp	15.9%-2.4pp	18.3%+0.9pp	17.4%-5.6pp	23.1%
Current Ratio	2.90+0.2	2.69-1.3	3.99-0.8	4.83+0.4	4.46+0.1	4.33
Debt-to-Equity	0.370.0	0.37+0.1	0.29-0.0	0.30-0.0	0.33-0.0	0.35
FCF Margin	26.6%+33.8pp	-7.2%-41.0pp	33.8%-10.1pp	44.0%+12.2pp	31.8%-16.4pp	48.2%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	85.4%-1.1pp	86.5%+0.3pp	86.3%-0.6pp	86.9%+1.4pp	85.5%-0.4pp	85.8%-0.1pp	85.9%-1.3pp	87.3%
Operating Margin	37.8%-0.8pp	38.6%-0.3pp	38.8%+16.1pp	22.8%-12.5pp	35.2%-5.0pp	40.3%+173.1pp	-132.8%-175.2pp	42.4%
Net Margin	37.3%+2.1pp	35.2%+0.4pp	34.8%+11.5pp	23.3%-8.0pp	31.4%-6.4pp	37.7%+173.5pp	-135.8%-176.7pp	40.9%
Return on Equity	6.4%+0.1pp	6.3%+0.2pp	6.0%+2.1pp	3.9%-1.6pp	5.6%-1.1pp	6.7%+31.0pp	-24.3%-30.3pp	5.9%
Return on Assets	4.6%+0.3pp	4.4%+0.1pp	4.3%+1.5pp	2.8%-1.2pp	4.0%-0.6pp	4.7%+22.5pp	-17.8%-22.4pp	4.6%
Current Ratio	2.90+0.5	2.36-0.2	2.52-0.1	2.65-0.0	2.69+0.2	2.47-0.1	2.52-1.0	3.50
Debt-to-Equity	0.37-0.1	0.44+0.0	0.40+0.0	0.39+0.0	0.37-0.0	0.42+0.1	0.36+0.1	0.29
FCF Margin	10.9%-26.1pp	37.0%+5.8pp	31.3%+3.2pp	28.1%+11.2pp	16.9%-30.1pp	47.0%+191.5pp	-144.5%-190.5pp	46.0%

Similar Companies

Alnylam Pharmaceuticals Inc ALNY

$42.3B

Regeneron Pharmaceuticals REGN

$80.5B

Argenx Se ARGX

$46.3B

BIONTECH BNTX

$22.9B

BeOne Medicines Ltd. ONC

$34.5B

Frequently Asked Questions

What is Vertex Pharmaceuticals Inc's annual revenue?

Vertex Pharmaceuticals Inc (VRTX) reported $12.0B in total revenue for fiscal year 2025. This represents a 8.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Vertex Pharmaceuticals Inc's revenue growing?

Vertex Pharmaceuticals Inc (VRTX) revenue grew by 8.9% year-over-year, from $11.0B to $12.0B in fiscal year 2025.

Is Vertex Pharmaceuticals Inc profitable?

Yes, Vertex Pharmaceuticals Inc (VRTX) reported a net income of $4.0B in fiscal year 2025, with a net profit margin of 32.9%.

What is Vertex Pharmaceuticals Inc's EBITDA?

Vertex Pharmaceuticals Inc (VRTX) had EBITDA of $4.4B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Vertex Pharmaceuticals Inc's gross margin?

Vertex Pharmaceuticals Inc (VRTX) had a gross margin of 86.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Vertex Pharmaceuticals Inc's operating margin?

Vertex Pharmaceuticals Inc (VRTX) had an operating margin of 34.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Vertex Pharmaceuticals Inc's net profit margin?

Vertex Pharmaceuticals Inc (VRTX) had a net profit margin of 32.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Vertex Pharmaceuticals Inc's return on equity (ROE)?

Vertex Pharmaceuticals Inc (VRTX) has a return on equity of 21.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Vertex Pharmaceuticals Inc's free cash flow?

Vertex Pharmaceuticals Inc (VRTX) generated $3.2B in free cash flow during fiscal year 2025. This represents a 504.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Vertex Pharmaceuticals Inc's operating cash flow?

Vertex Pharmaceuticals Inc (VRTX) generated $3.6B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Vertex Pharmaceuticals Inc's total assets?

Vertex Pharmaceuticals Inc (VRTX) had $25.6B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Vertex Pharmaceuticals Inc's capital expenditures?

Vertex Pharmaceuticals Inc (VRTX) invested $437.6M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Vertex Pharmaceuticals Inc spend on research and development?

Vertex Pharmaceuticals Inc (VRTX) invested $3.9B in research and development during fiscal year 2025.

Does Vertex Pharmaceuticals Inc buy back shares?

Yes, Vertex Pharmaceuticals Inc (VRTX) spent $2.0B on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Vertex Pharmaceuticals Inc have outstanding?

Vertex Pharmaceuticals Inc (VRTX) had 254M shares outstanding as of fiscal year 2025.

What is Vertex Pharmaceuticals Inc's current ratio?

Vertex Pharmaceuticals Inc (VRTX) had a current ratio of 2.90 as of fiscal year 2025, which is generally considered healthy.

What is Vertex Pharmaceuticals Inc's debt-to-equity ratio?

Vertex Pharmaceuticals Inc (VRTX) had a debt-to-equity ratio of 0.37 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Vertex Pharmaceuticals Inc's return on assets (ROA)?

Vertex Pharmaceuticals Inc (VRTX) had a return on assets of 15.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Vertex Pharmaceuticals Inc's Altman Z-Score?

Vertex Pharmaceuticals Inc (VRTX) has an Altman Z-Score of 11.67, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Vertex Pharmaceuticals Inc's Piotroski F-Score?

Vertex Pharmaceuticals Inc (VRTX) has a Piotroski F-Score of 6 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Vertex Pharmaceuticals Inc's earnings high quality?

Vertex Pharmaceuticals Inc (VRTX) has an earnings quality ratio of 0.92x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Vertex Pharmaceuticals Inc cover its interest payments?

Vertex Pharmaceuticals Inc (VRTX) has an interest coverage ratio of 313.8x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Vertex Pharmaceuticals Inc?

Vertex Pharmaceuticals Inc (VRTX) scores 75 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.